The cancer-focused antibody developer has secured $58.5m in a US flotation that involved existing investors Celgene and Eli Lilly buying more than $7m of shares.

Big data software provider Cloudera has gone public, but the gap between its market cap and the valuation at which Intel invested three years ago may be an ill omen for backers of other unicorns.

The oncology drug developer has raised $92.5m in VC funding, $11.5m of which came from MedImmune Ventures, the CVC unit that now owns a 16.7% stake.

The oncology drug developer has raised $92.5m in VC funding, $11.5m of which came from MedImmune Ventures, the CVC unit that now owns a 16.7% stake.

The logistics service provider is set to float in the US in an initial public offering of up to $1bn that will give exits to Alibaba, Foxconn, Fosun and Cainiao Network.

Cloudera will raise up to $210m in its initial public offering, with existing backer Intel considering buying 10% of the issued shares at half the valuation of its initial investment.

Sanofi and Takeda-backed Ovid Therapeutics has filed to raise $86.3m in an initial public offering and plans to use the proceeds to advance its neurological disease treatments.

The wind and solar power producer has raised more than $850m in total equity funding, including $200m from Tokyo Electric Power and Chubu Electric Power this year.

The corporate-backed music platform is reportedly mulling a public market listing that would not raise money but which would allow investors to divest their shares.

Data management platform Cloudera has filed for an initial public offering that will give exits to Intel - its largest shareholder - and Alphabet.